Skip to content
HowShorted

Axsome Therapeutics, Inc. short interest in 2020

In 2020, Axsome Therapeutics, Inc.'s disclosed short interest ran from 11.55% of shares outstanding on 15 Jan 2020 to 9.27% on 31 Dec 2020, a change of -2.28 percentage points. The year's high was 11.78% on 31 Jan 2020 and its low 8.94% on 30 Nov 2020, averaging 10.17% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.93 days on 30 Nov 2020. Full history: Axsome Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Axsome Therapeutics, Inc. in 2020

2020 in figures

Start of year
11.55% (15 Jan 2020)
End of year
9.27% (31 Dec 2020)
Change
-2.28 pp
High
11.78% (31 Jan 2020)
Low
8.94% (30 Nov 2020)
Average
10.17%
Highest days to cover
16.93 (30 Nov 2020)
SEC filings marked
8

Every report in 2020

Axsome Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202011.55%3.69
31 Jan 202011.78%7.25
14 Feb 202011.43%7.08
28 Feb 202010.97%5.34
13 Mar 202011.22%5.4610-K filed, results (8-K)
31 Mar 202010.50%3.01
15 Apr 202011.39%4.98
30 Apr 20209.67%2.85
15 May 20209.24%5.20results (8-K), 10-Q filed
29 May 20209.16%6.60
15 Jun 20209.56%8.09
30 Jun 202010.40%5.58
15 Jul 202010.43%10.48
31 Jul 202010.43%12.40
14 Aug 202010.40%11.3010-Q filed, results (8-K)
31 Aug 202010.31%13.99
15 Sep 20209.84%7.69
30 Sep 202010.25%8.37
15 Oct 20209.71%14.88
30 Oct 20209.23%14.49
13 Nov 20209.26%11.2010-Q filed, results (8-K)
30 Nov 20208.94%16.93
15 Dec 20209.05%9.30
31 Dec 20209.27%11.13

See also: Axsome Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.